From: Clinical characteristics and risk factors for gout flare during the postsurgical period
All (n = 70) | Flare (n = 31) | No flare (n = 39) | P value | |
---|---|---|---|---|
Age, years | 62.6 ± 14.8 | 64.1 ± 16.2 | 61.4 ± 13.7 | 0.463 |
Male | 60 (85.7) | 28 (90.3) | 32 (82.1) | 0.495 |
BMI, kg/m2 | 25.0 ± 4.3 | 24.6 ± 4.5 | 25.3 ± 4.2 | 0.499 |
Disease duration, months | 54.3 ± 48.4 | 54.0 ± 54.6 | 54.6 ± 43.8 | 0.964 |
Comorbidities | ||||
Hypertension | 43 (61.4) | 17 (54.8) | 26 (66.7) | 0.313 |
Diabetes Mellitus | 14 (20.0) | 7 (22.6) | 7 (18.4) | 0.669 |
Chronic kidney disease | 37 (52.9) | 14 (45.2) | 23 (59) | 0.250 |
Dialysis | 15 (21.4) | 7 (22.6) | 8 (20.5) | 0.834 |
Cardiovascular disease | 6 (8.6) | 3 (9.7) | 3 (7.7) | 1.000 |
Urinary stone | 6 (8.6) | 4 (12.9) | 2 (5.1) | 0.395 |
Presurgical uric acid, mg/dL | 7.8 ± 2.3 | 8.8 ± 2.4 | 7.1 ± 1.9 | 0.001 |
Postsurgical uric acid, mg/dL | 6.5 ± 2.0 | 6.2 ± 2.3 | 6.7 ± 1.7 | 0.281 |
Amount of uric acid change | 1.9 ± 2.1 | 2.8 ± 2.4 | 1.2 ± 1.4 | 0.001 |
Medication | ||||
Any gout medicationsa | 40 (57.1) | 9 (29.0) | 31 (79.5) | < 0.001 |
Allopurinol | 30 (42.9) | 6 (19.4) | 24 (61.5) | < 0.001 |
Febuxostat | 6 (8.6) | 1 (3.2) | 5 (12.8) | 0.161 |
Colchicine | 17 (24.3) | 5 (16.1) | 12 (30.8) | 0.127 |